<DOC>
	<DOCNO>NCT00003821</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness aminopterin treat patient refractory recurrent endometrial cancer .</brief_summary>
	<brief_title>Aminopterin Treating Patients With Recurrent Refractory Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate antitumor activity aminopterin patient persistent , recurrent , refractory endometrial carcinoma fail prior first line cytotoxic chemotherapy . II . Determine quantitative qualitative toxic effect aminopterin patient population . III . Determine overall patient survival time progression patient . IV . Assess pharmacokinetic profile patient . OUTLINE : Patients receive oral aminopterin every 12 hour twice weekly . Treatment continue 15 month absence disease progression unacceptable toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 15-25 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm persistent , recurrent , refractory endometrial carcinoma fail prior first line chemotherapy Bidimensionally measurable disease physical exam medical imaging technique ( sonography acceptable lesion ( ) clearly define measurable two dimension ) Ascites pleural effusion measurable PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : At least 2 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : At least 4 week since prior surgery recover Other : At least 4 week since prior therapy direct malignant endometrial tumor ( ) At least 4 week since prior folatecontaining vitamins No concurrent folatecontaining vitamins No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>